一、新兽药产品基本情况 新兽药名称：牛产气荚膜梭菌病（A 型）基因工程亚单位疫苗 注册分类：二类 新兽药注册证书号：（2025）新兽药证字 116 号 研制单位：金宇保灵生物药品有限公司、浙江海隆生物科技股份有限公司 证券代码：600201 证券简称：生物股份 公告编号：临 2025-057 金宇生物技术股份有限公司 关于子公司取得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据国家《兽药管理条例》和《兽药注册办法》规定，经国家农业农村部审 查，批准金宇生物技术股份有限公司（以下简称"公司"）全资子公司金宇保灵 生物药品有限公司（以下简称"金宇保灵"）与其他公司共同研制的牛产气荚膜 梭菌病（A 型）基因工程亚单位疫苗为新兽药，并核发了《新兽药注册证书》。 详情如下： 在上述新兽药产品上市销售前，金宇保灵将按照《兽药管理条例》与《兽药 产品批准文号管理办法》的要求，开展产品批准文号申请及报审相关工作。在取 得兽药产品批准文号后，该新兽药产品方具备上市销售的条件。 四、新兽药产品对公司的影响 主要成 ...

Core Viewpoint - The company has received approval for a new veterinary drug, a genetically engineered subunit vaccine for Clostridium chauvoei (Type A), aimed at preventing sudden death in cattle caused by this pathogen [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has collaborated with other companies to develop the new veterinary drug [1] - The approval was granted by the Ministry of Agriculture and Rural Affairs of China, following the review of the National Veterinary Drug Administration regulations [1] Group 2: Product Details - The vaccine is designed to prevent sudden death syndrome in cattle caused by Type A Clostridium chauvoei [1] - Immunity is achieved within 7 days post-second vaccination, with an immunity duration of 5 months [1]

Core Viewpoint - The animal health sector experienced a decline of 0.85% on October 16, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.1%, while the Shenzhen Component Index fell by 0.25 [1]. Group 1: Market Performance - The closing price of *ST Lvkang was 27.48, with an increase of 5.01%, while other stocks in the sector showed mixed results [1]. - The total trading volume for the animal health sector was significant, with *ST Lvkang recording a volume of 14,900 hands and a transaction amount of 40.81 million yuan [1]. - The overall market saw a net outflow of 126 million yuan from the animal health sector, with retail investors contributing a net inflow of 91.62 million yuan [2]. Group 2: Individual Stock Analysis - *ST Lvkang had a net inflow of 5.23 million yuan from major funds, while Xianfeng Holdings saw a net outflow of 3.36 million yuan [3]. - The stock of RuiPu Bio had a significant net outflow of 25.44 million yuan from major funds, despite a retail net inflow of 39.62 million yuan [3]. - The stock of HaiLi Bio experienced a net outflow of 4.47 million yuan from major funds, with a retail net inflow of 2.64 million yuan [3].

Core Viewpoint - The company, BioPharm (600201.SH), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, a genetically engineered subunit vaccine for Clostridium perfringens type A, developed in collaboration with other companies [1] Group 1 - The vaccine has been approved as a new veterinary drug according to national regulations [1] - The approval includes the issuance of a New Veterinary Drug Registration Certificate [1] - The vaccine is developed by the company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd. [1]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 58.13% and a recent decline of 2.09% on October 16, 2023 [1][2]. Financial Performance - For the first half of 2025, the company reported a revenue of 620 million yuan, reflecting a year-on-year growth of 1.28%, while the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan [2]. - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3]. Stock Market Activity - The stock has seen a trading volume of 288 million yuan on October 16, 2023, with a turnover rate of 2.36% and a total market capitalization of 12.007 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on July 17, 2023, where it recorded a net purchase of 123 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 3.84% to 54,900, with an average of 20,405 circulating shares per person, a decrease of 3.70% [2]. - The top ten circulating shareholders include significant institutional investors, such as Guotai Zhenzhong Livestock Breeding ETF and Southern Zhenzhong 1000 ETF, which have increased their holdings [3].

Core Insights - The animal health sector experienced a 1.5% increase on October 15, with Bio-Pharmaceuticals leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Bio-Pharmaceuticals (600201) closed at 11.03, up 4.06% with a trading volume of 563,500 shares and a turnover of 614 million yuan [1] - Other notable stocks include: - Shunlian Bio (688098) at 10.48, up 2.95% [1] - Ruipu Bio (300119) at 22.56, up 2.31% [1] - Yongshun Bio (920729) at 676, up 1.93% [1] - Dayu Bio (920970) at 9.45, up 1.61% [1] Capital Flow - The animal health sector saw a net outflow of 5.71 million yuan from institutional investors, while retail investors contributed a net inflow of 1.83 million yuan [2] - The capital flow for key stocks includes: - Ruipu Bio had a net inflow of 25.55 million yuan from institutional investors [3] - Hai Li Bio experienced a net outflow of 3.22 million yuan from institutional investors [3] - KQ Bio (688526) had a net inflow of 5.26 million yuan from retail investors [3]

Core Viewpoint - The animal health sector experienced a decline of 0.68% on October 14, with Xianfeng Holdings leading the drop. The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1]. Stock Performance Summary - Zhongmu Co., Ltd. (600195) closed at 7.35, up 1.66% with a trading volume of 120,000 shares and a transaction value of 87.91 million yuan [1]. - Yongshun Biological (920729) closed at 9.31, up 0.54% with a trading volume of 13,800 shares and a transaction value of 12.82 million yuan [1]. - Biological Co. (600201) closed at 10.60, up 0.28% with a trading volume of 624,200 shares and a transaction value of 672 million yuan [1]. - Other notable stocks include Ruip Bio (300119) down 0.45% and Jinhai Bio (002688) down 0.98% [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 8.12 million yuan from institutional investors, while retail investors had a net inflow of 4.61 million yuan [2][3]. - Major stocks like Biological Co. (600201) experienced a net inflow of 62.91 million yuan from institutional investors, while Xianfeng Holdings (002141) saw a net outflow of 9.04 million yuan [3].

Core Points - The company announced a change in its subsidiary's name and legal representative due to operational development needs [2] - The necessary business registration changes have been completed, and a new business license has been issued [2]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 10.57 | 4.04% | 70.36万 | 7.25亿 | | 002688 | 金河生物 | 7.11 | 3.95% | 55.43万 | 3.93亿 | | 002141 | 后丰控股 | 3.96 | 2.86% | 45.10万 | 1.76亿 | | 300119 | 瑞普生物 | 22.15 | 1.28% | 11.53万 | 2.54亿 | | 688098 | 申联生物 | 10.46 | 0.97% | 5.93万 | 6137.71万 | | 603566 | 曾菜柯 | 14.16 | 0.43% | 4.88万 | 6872.97万 | | 300871 | 回盛生物 | 21.30 | -0.14% | 5.48万 | 1.16亿 | | 603718 | 海利生物 | 6.88 | -0.29% | 4.90万 | 3342.64万 | | 920970 | 大禹生物 | 9.3 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-056 金宇生物技术股份有限公司关于 控股子公司变更名称等信息暨完成工商变更的公告 本次控股子公司名称等信息变更是基于经营发展需要，不会导致公司主营业务 发生重大变化，不会对公司未来经营发展产生不利影响。 特此公告。 2.统一社会信用代码：91211000774602945W 3.法定代表人：高日明 4.注册资本：11,500 万元 5.成立日期：2005 年 4 月 30 日 6.住所：辽阳市太子河区南驻路 12 号 7.经营范围：生产、销售：细胞毒活疫苗、胚毒活疫苗、胚毒灭活疫苗、禽流 感灭活疫苗、卵黄抗体、细胞毒灭活疫苗、细菌灭活疫苗、细菌活疫苗；道路货物 运输；非国家强制免疫兽用生物制品销售。(依法须经批准的项目,经相关部门批准 后方可开展经营活动)。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，金宇生物技术股份有限公司（以下简称"公司"）控股子公司金宇益康 生物技术(辽宁)股份有限公司因经营发展需要，对其公司名称、法定代表人等信息 进行了变更 ...